[Ip-health] Medicines Patent Pool Collaboration with ViiV to increase availability of medicines for paediatric HIV

Kaitlin Mara kmara at medicinespatentpool.org
Thu Feb 28 06:49:21 PST 2013

Hi all,

The Medicines Patent Pool yesterday announced a new collaboration with
GlaxoSmithKline, Pfizer and Shionogi via the joint venture ViiV
Healthcare. Under the collaboration, MPP & ViiV have agreed to work
together in several areas to make more quality medicines and needed
formulations for children available in developing countries.

These areas include: a royalty-free licence on one key HIV medicine,
abacavir, in the 118 countries where 98.7% of children with HIV reside; a
commitment to license pipeline products for paediatric use in 118
countries once those products are approved by drug regulators; a
commitment for ViiV to provide technology transfer to aid generic
manufacture, and to provide access to data on medicines quality and
efficacy; and planned partnerships with third parties to help bring to
market as-yet undeveloped treatments to to speed the availability of those
treatments in developing countries.

The full press release on this collaboration is available from MPP's
website (in English, Spanish, and French) here:

Transparency is important to the MPP, and we have posted the full texts of
the collaboration, and the abacavir licence on our website here:

The MPP has an advisory group made up of experts in public health,
intellectual property law, medicine and communities of people living with
HIV. This group provides strategic advice for ongoing negotiations and
reviews licences before they are signed. The group's review of the ViiV
licence is available here [pdf link]:

All the best,

Kaitlin Mara | Communications Manager | Medicines Patent Pool
direct: +41 22 791 6344 | mobile: +41 79 825 4786 |
kmara at medicinespatentpool.org

More information about the Ip-health mailing list